Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547794 · ClinicalTrials.gov registry record
AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF
A clinical trial, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- 14
- Enrollment target
NCT00547794 is a clinical trial that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 14 participants.
The verdict
NCT00547794 was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if the combination of AVJ ablation followed by BiV pacing significantly improves functional status and exercise capacity compared to pharmacologic rate control in patients with chronic AF and depressed ejection fraction, regardless of rate or QRS duration.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547794
The ClinicalTrials.gov registry entry for NCT00547794 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00547794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547794 about?
NCT00547794 is a clinical study titled "AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF". The purpose of the study is to determine if the combination of AVJ ablation followed by BiV pacing significantly improves functional status and exercise capacity compared to pharmacologic rate control in patients with chronic AF and depressed ejection fraction, regardless of rate or QRS duration.
What is the current status of trial NCT00547794?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2007-06. Estimated completion is 2010-11.
Who is sponsoring clinical trial NCT00547794?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.